Disc Medicine (IRON) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Organon (OGN) has outperformed Disc Medicine (IRON) over the past year, gaining 92.9% versus a loss of 18.9%. Over five years, IRON leads with a -14.2% price change compared with -55.4% for OGN. Organon is the larger company by market cap ($3.65 billion vs $3.42 billion), about 1.1 times the size.
Organon pays a dividend yielding 0.58%, while Disc Medicine does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | OGN |
|---|---|---|
| Share price | $75.14 | $13.89 |
| Market cap | $3.42B | $3.65B |
| 1-day change | -1.27% | -0.14% |
| YTD return | -5.38% | +93.72% |
| 1-year return | -18.86% | +92.92% |
| 5-year return | -14.22% | -55.38% |
| P/E ratio (TTM) | — | 17.81 |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-6.34 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | — | $6.22B |
| Revenue growth (YoY) | — | -2.92% |
| Net income (latest FY) | $-212.18M | $187.00M |
| Gross margin | — | 53.30% |
| Net margin | — | 3.01% |
| 52-week high | $99.50 | $13.94 |
| 52-week low | $40.00 | $5.69 |
| Distance from 52-week high | -24.48% | -0.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +69.94% | -25.63% |
| Average volume | 951.56K | 2.74M |
| Shares outstanding | 45.54M | 262.62M |
| Employees | 173 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed IRON by 111.8 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
IRON vs OGN FAQ
Which is bigger, Disc Medicine or Organon?
Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.42B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or OGN?
OGN returned +92.92% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Disc Medicine or Organon?
Organon pays a dividend yielding 0.58%, while Disc Medicine does not currently pay a regular dividend.
Are Disc Medicine and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.